Ranbaxy Shifts Lipitor Generic Production From U.S. To New India Plant
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories has begun transferring U.S. production of its generic version of Pfizer’s Lipitor (atorvastatin) cholesterol drug back home to India at its newly approved production facility in Mohali.
You may also be interested in...
QUOTED. 13 December 2019. Todd Garner
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Real-World Evidence Fails Another Test At US FDA
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.
Need a specific report? 1000+ reports available
Buy Reports